Sandoz Follows US Denosumab Filing With European Acceptance
Dual Filings With EMA For Prolia/Xgeva Biosimilars Confirmed By Novartis Unit
Sandoz has confirmed dual European filings for its denosumab biosimilar rival to Prolia and Xgeva, a few months after it submitted its candidate in the US.
You may also be interested in...
Fresenius Kabi has welcomed “another testimonial of our efforts to expand our biosimilar portfolio,” with an update for its FKS518 biosimilar denosumab candidate.
Mitsubishi Gas Chemical Company and GlycoNex have begun a Phase I trial in Japan for their SPD8 denosumab biosimilar. The partners are also “actively pursuing global development plans” for the rival to Prolia and Xgeva.
In a busy week for Alvotech, the firm has announced an expansion of its partnership with Advanz to cover five further European biosimilars, at the same time as revealing two new pipeline assets. Meanwhile, the company has also dropped three products from an existing European partnership with Stada and has also terminated a development deal with BiosanaPharma.